This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. A team of scientists—led by Yamin Zhang, Ph.D., and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. Our Social Media Platform Web: [link] LinkedIn: [link] Twitter: [link] The post Subcutaneous Medications and DrugDeliverySystems appeared first on Blog.
Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drugdelivery have been highlighted in the figure.
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
Global Transdermal DrugDeliverySystems Market Research Report 2021: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 – ResearchAndMarkets.com Global Transdermal DrugDeliverySystems Market Research Report 2021: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 … Continue (..)
AMR and multi-drug resistance are said to result in the deaths of more than five million people per year. Nine universities and research institutes, along with seven medical and industry partners, will work on the IN-ARMOR project across nine EU countries.
Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis. This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drugdeliverysystem using synthetic amyloid beta (AÎ) peptides.
Hence, a precision therapy or we can say a target therapy (involving intracellular drugdelivery) is much needed to all the patients suffering from cancer. Here is how the intracellular drugdelivery comes into action for majority of the fatal diseases that requires target therapy. The answer is yes.
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. By having the drug already dosed inside the chamber and no need to draw it from a vial into a syringe, the process is streamlined and the risk of a potential dosing error is eliminated.
Robotics, for example, has facilitated the automation of medicine preparation and distribution, controlled drugdeliverysystems, and machine-readable coding on medicine packages. Newly emerging technologies have helped in improving the effectiveness and safety of non-sterile commercial dose products.
Similarly, the target delivery approach in healthcare would take the drugs directly to right where it’s needed: the disease site, icing apt treatment. We have put in our best effort to make it easily graspable what are the intracellular drugdelivery technologies and how it can ensure effective treatment for fatal disease.
Nano-based deliverysystems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugs market size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.
However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs. Web: [link].
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. million adults in the United States.
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
The VTT Technical Research Centre of Finland has addressed this issue by developing a fully recyclable, modular ECG patch constructed from VTT’s novel cellulose e-skin material. Aayush Jaiswal, research scientist at VTT said, “Ours is the first nanocellulose-based ECG patch with no plastic additives.
Over the years, applications of exosomes in therapeutics have undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field. Exosome Service Providers – Current Market Landscape. Web: [link].
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
However, certain biological targets have long eluded drug development efforts. Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them. For further information on this domain, check our report here.
Clinical trials are the backbone of medical research, paving the way for new treatments, drugs, and therapeutic procedures that can potentially revolutionize healthcare. A Data Safety Monitoring Board (DSMB) is an independent committee composed of clinical research experts, statisticians, and often, ethicists.
Certain areas where this technology is working hand-in-hand with healthcare are: Unsustainable healthcare systems into sustainable ones Equalizing the relationship between medical professionals and patient Provide cheaper, faster and more effective solutions for diseases. Drug Development. Management & Administration.
In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy.
Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. Over 10,000 articles, indicative of the ongoing research and innovation in this field, have been published in scientific literature. ACADEMIC GRANTS ANALYSIS.
Application of Synthetic mRNA Several studies conducted by healthcare companies and research institutions have demonstrated the potential of mRNA. The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise.
Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013.
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field. High Number of Patents are Suggestive of the Widespread Research in this Domain. Web: [link].
In addition to therapeutics, these complex molecules act as a significant resource in various research applications. You may also be interested in the following titles: Live Biotherapeutic Products and Microbiome Manufacturing Marke t Next Generation Complement Therapeutics Market Intranasal Therapeutics and DrugDeliverySystems Market.
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Till date, 14 oligonucleotide-based therapies have been approved. Our Social Media Platform. Web: [link]. LinkedIn: [link].
Real World Data and Blue Ocean Strategy Real-world data is particularly useful for researchers, as it provides valuable insights from patient data and knowledge that can impact many decision-making processes. New Drug Formulations as a Blue Ocean Strategy New drug formulations can help improve patient adherence and reduce side effects.
Retinal vein occlusion drug market. The treatment options such as Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs, and Intravitreal injection of corticosteroid drugs. Intraocular injections of steroids are another potential treatment for eyes that don’t respond to anti-VEGF drugs.
Therapies such as dexamethasone drugdeliverysystem and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Looking at its potential, the drug is also being watched out in diabetic macular edema in combination with intravitreal anti-VEGF drugs.
Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. As a matter of fact, recently many drug developers have initiated formulating novel therapeutic interventions that utilize nanoparticles as a major component ( nanomedicines ). Our Social Media Platform.
Recently the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMINI 2 clinical studies. A Minipump Continuous Drug Infusion Dog Model System to Identify Candidate Drugs and DrugDelivery Rates for Intracameral IOP-lowering Implants.
Drugs such as pembrolizumab (Merck’s Keytruda) and nivolumab (Bristol Myers Squibb’s Opdivo) have revolutionized the treatment options for skin cancer. Ongoing research on molecular diagnostics and AI-powered diagnostic tools has helped enhance the early detection and treatment of skin cancer, promising improved patient outcomes.
Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Biopharmaceutical excipients can range from simple inert entities to complex compounds.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
It is worth mentioning that the first radiopharmaceutical peptide-drug conjugate Luthathera was approved by United States Food and Drug Administration (USFDA) in 2018 for the treatment of gastroenteropancreatic neuroendocrine tumors. It consists of somatostatin-derived peptide and DOTA complexed with radioactive isotope 77 Lu.
Vice President, Late Development and Global Medical Affairs, Janssen Research & Development, LLC. “We TAR-200 is an investigational drugdeliverysystem, enabling controlled release of gemcitabine into the bladder, increasing dwell time and local drug exposure. DRUG INTERACTIONS. About TAR-200.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Since then, the drug has been used off-label in breast cancer and other types of cancer.
A robust drug patent portfolio is not just an assetit’s a critical tool for success. As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. These protect the core molecule or compound that gives a drug its therapeutic effect.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content